PDK2 and lung carcinoma: In addition, since PDK inhibition was more effective in suppressing cell growth of the resistant A549-R cells than the parental A549 cells, these results suggest that PDK2 may serve as an effective target for overcoming paclitaxel resistance in patients with lung cancer.